Ultrasound and Assessment of Ovarian Cancer Risk

Twickler, Diane M.; Moschos, Elysia

doi:10.2214/ajr.09.3562

Cited by 38 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early symptoms of OvCa are rare, and when present they are nonspecific and similar to other diseases, including benign gynecological conditions [5, 6]. Present imaging techniques often are unable to distinguish benign and malignant ovarian tumors [7, 8]. …”

Section: Introductionmentioning

confidence: 99%

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors

Liggett

Melnikov

Yi³

et al. 2011

Gynecologic Oncology

View full text Add to dashboard Cite

Objective-Epithelial ovarian carcinoma (OvCa) is rarely detected early, and it is also difficult to determine whether an adnexal mass is benign or malignant. Previously, we noted differences in methylation patterns of cell-free plasma DNA (cfpDNA) in women without disease compared to patients with OvCa. In this work we investigated whether methylation patterns of cfpDNA can differentiate between benign and malignant tumors.Methods-Methylation patterns in cfpDNA were determined in three cohorts (30 samples each) using a microarray-based assay (MethDet 56). Principal component analysis, supervised clustering, linear discrimination analysis, and 25 rounds of 5-fold cross validation were used to determine informative genes and assess the sensitivity and specificity of differentiating between OvCa vs. healthy control (HC), benign ovarian disease (mostly serous cystadenoma, BOD) vs. HC, and OvCa vs. BOD samples.Results-Differential methylation of three promoters (RASSF1A, CALCA, and EP300) differentiated between OvCa vs. HC with a sensitivity of 90.0% and a specificity of 86.7%. Three different promoters (BRCA1, CALCA, and CDKN1C) were informative for differentiating between BOD vs. HC, with a sensitivity of 90.0% and a specificity of 76.7%. Finally, two promoters (RASSF1A and PGR-PROX) were informative for differentiating between OvCa vs. BOD, with a sensitivity of 80.0% and a specificity of 73.3%.

show abstract

Section: Introductionmentioning

confidence: 99%

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors

Liggett

Melnikov

Yi³

et al. 2011

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Worldwide, B225 500 women are diagnosed with ovarian cancer annually, with an estimated 140 200 women-associated deaths [2]. Nevertheless, the available imaging techniques are often unable to distinguish benign from malignant ovarian neoplasm with high precision [3]. The high false-positive rates of CA-125 screening test often leads to unnecessary medical interventions [4].…”

Section: Introductionmentioning

confidence: 99%

Prediction of ovarian malignancy using plasma cell-free DNA

El-Garf

Elshair

Aref

et al. 2015

Medical Research Journal

View full text Add to dashboard Cite

Objective Evaluation of cell-free DNA (cf-DNA) as a noninvasive tool to discriminate between malignant and benign ovarian growth.Patients and methods DNA was extracted from the plasma of 50 women with ovarian lesion. A total of 20 women with pathologically proven malignancy and 30 women with benign ovarian lesions were included. Quantification of cf-DNA was performed using real-time PCR. cf-DNA was correlated with the histopathology. ResultsThe preoperative plasma cf-DNA level was statistically significantly higher (P < 0.0001) in the malignant group (3.6 ± 1.7 ng/ll) compared with the benign group (0.71 ± 0.69 ng/ml) with 5.04-fold higher in the malignant group than in the benign counterpart. The mean level of cf-DNA in women with benign ovarian lesion (0.71 ± 0.69 ng/ml) did not reach statistically significant difference (P = 0.2) when compared with the mean level among women having endometriotic cysts (0.60 ± 0.44 ng/ml). In addition, there was no correlation between the CA-125 and cf-DNA levels (r = 0.127, P = 0.07), with sensitivity of 96% and specificity of 84%, with a cutoff limit of 1.4 ng/ml in diagnosing malignancy.Conclusion Detection of cf-DNA holds promise as a diagnostic test for women with ovarian cancer. We recommend its incorporation into the workup investigations for women attending with adnexal mass.

show abstract

“…15,16 Today, screening of ovarian cancer using CA125 is carried out in combination with physical examination. 17,18 Its early detection is important to achieve effective OC diagnosis in order that treatment regimen can be initiated at the onset of the disease. 19 …”

Section: Introductionmentioning

confidence: 99%

Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods

Al-Ogaidi

Aguilar

Suri

et al. 2013

Analyst

View full text Add to dashboard Cite

An enzyme-linked immunoassay based on the dual signal transduction mechanisms has been developed for detection of ovarian cancer biomarker CA125. The immunoassays use a nanoelectrode array (NEA) chip and absorbance methods for the dual detection. The NEA is used to confirm the optical detection of CA125 that is carried out in a high-binding 96-well plate. An alkaline phosphatase (AP) enzyme was used to label the detection antibody to allow for both the optical and electrochemical detection of CA125. Two kinds of substrates were catalyzed by the AP enzyme. Para-nitrophenylphosphate (PNPP) produces chromogenic para-nitrophenol (PNP), which can be optically detected at 405 nm. Para-aminophenylphosphate (PAPP) produces electroactive para-aminophenol (PAP), which can be detected amperometrically between −0.1 to 0.3 V. The linear ranges have been determined to be 5–1000 U/mL and 5–1000 U/mL for the optical and electrochemical immunoassays, respectively. The limit of detection of the optical immunoassay is 1.3 U/mL and 40 U/mL for the optical and electrochemical methods, respectively.

show abstract

Ultrasound and Assessment of Ovarian Cancer Risk

Cited by 38 publications

References 35 publications

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors

Prediction of ovarian malignancy using plasma cell-free DNA

Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods

Contact Info

Product

Resources

About